Induction of Plasminogen Activator Inhibitor-1 in Endothelial Cells by Basic Fibroblast Growth Factor and Its Modulation by Fibric Acid
A lterations in the function of the fibrinolytic system have been implicated in the pathogenesis of thromboembolic phenomena and vasculopathy. 1 Fibrinolytic system activity is regulated at transcriptional, translational, and posttranslational levels and is influenced by specific growth factors. 2 Plasminogen activator inhibitor (PAI)-1, the primary physiological inhibitor of plasminogen activators, is a pivotal inhibitor of fibrinolysis 2 and of proteolytic processes 3 associated with vascular remodeling 4 and fibrosis. 5 Endothelial cells (ECs) elaborate fibrinolytic system proteins, including tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator. 2, 6 Basic fibroblast growth factor (bFGF), a growth factor elaborated by vascular cells, modulates the expression of plasminogen activators in ECs and smooth muscle cells. [7] [8] [9] [10] Excessive plasmin generation and proteolysis induced by bFGF-mediated overproduction of plasminogen activators may interfere with cell adhesion or atherosclerotic plaque development. However, the influence, if any, of bFGF on the synthesis of PAI-1 in ECs has not been elucidated. The potential influence may well contribute to physiological or pathophysiological consequences of the elaboration of bFGF. The local synthesis of PAI-1 and the balance between plasminogen activation and inhibition determine the generation of plasmin, which, in turn, influences regional fibrinolytic balance, thus modulating the atherothrombotic 11 and angiogenic 12 properties of ECs.
We have previously reported that a lipid-lowering fibric acid derivative, which activates peroxisome proliferator-activated receptor-␣ (PPAR␣), reduces PAI-1 expression in human hepatoma cells in vitro. 13 In the present study, we characterized the influence of bFGF and fibric acid on the elaboration of PAI-1 in vitro by cultured ECs and sought to delineate the potential mechanisms that may underlie increased PAI-1 expression in vivo.
Methods

Materials
Human umbilical vein ECs (HUVECs) were obtained from Clonetics. A human endothelium-derived cell line, ECV304 cells (ECV cells), were obtained from American Type Culture Collection. Penicillin-streptomycin solution, medium 199, DMEM, trypsin, genistein, and actinomycin D were purchased from Sigma Chemical Co. PD98059 was from Research Biochemical International, and GF109203X was from Tocris. Recombinant human bFGF was from Genzyme, and fenofibric acid was from Kaken. Mouse anti-human PAI-1 IgG was from American Diagnostica. Rabbit anti-human E26 transformation specific 1 (Ets-1)/Ets-2 IgG, which exhibits broad cross-reactivity with members of the Ets family proteins, was from Santa Cruz Biotechnology. All other chemicals were of the highest available commercial grade.
Cell Culture Procedures
HUVECs between the second and third passages were grown to confluence under 5% CO 2 at 37°C with EC basal medium (EBM-2, Clonetics). ECV cells were grown to confluence in medium 199 containing 10% calf serum (Hyclone), 100 U/mL penicillin, and 100 g/mL streptomycin. Confluent ECs were incubated in serum-free DMEM for 24 hours and then incubated with fresh serum-free DMEM containing bFGF. Media were collected and stored at Ϫ80°C. In some experiments, fenofibric acid was prepared as previously described, 13 and ECV cells were preincubated with fenofibric acid for 24 hours in serum-free DMEM before exposure to bFGF. When inhibitors were used, ECV cells were pretreated with the inhibitor for 1 hour before the addition of bFGF. Cell viability was determined by trypan blue exclusion and MTT assay (Sigma).
Assays for PAI-1 Activity, PAI-1 Antigen, tPA Antigen, and Total Protein PAI-1 activity was measured as previously described. 14 Human PAI-1 antigen in the media was measured by an ELISA specific for human PAI-1 (Biopool). Human tPA antigen in the media was measured by ELISA (American Diagnostica). Total protein in the conditioned media was assayed with the BCA protein assay (Pierce).
Assays for PAI-1 Antigen by Western Blotting
Equivalent amounts of protein from conditioned medium were diluted 1:1 with sample buffer (0.25 mol/L Tris-HCl [pH 6.8], 40% glycerol, 4% SDS, 20% ␤-mercaptoethanol, and 0.01% bromophenol blue) and loaded on a 10% SDS-polyacrylamide gel. PAI-1 antigen expression in the conditioned media was assayed by Western blotting as previously described 15 with antibodies specific for human PAI-1 and quantified by the method of Huang and Amero. 16 
Isolation of Total RNA and Northern Blotting
Total RNA was isolated by an acid guanidinium thiocyanatephenol-chloroform method. Northern blot analysis was performed as described previously. 13 Gel-purified polymerase chain reaction (PCR) fragments for PAI-1 (1112 to 1612) and ␤-actin, radiolabeled with [␣-32 P]dCTP by random priming, were used as probes. The radioactivity of hybridized bands was detected by autoradiography, which was then subjected to densitometry.
Promoter-Luciferase Vector and Expression Plasmid
The human PAI-1 promoter 5Ј flanking region 17 from Ϫ747 to 15 (762 bp) was amplified by PCR from human genomic DNA isolated from umbilical vein with the forward primer 5Ј-TCCAACCTCAGCCAGACAAG-3Ј (Ϫ747 to Ϫ727) and the reverse primer 5Ј-TCTCCTCGTGTCGACACAAA-3Ј (Ϫ5 to 15), respectively. The PCR product was gel-purified and subcloned into the multiple cloning sites of the pT7Blue T-Vector (Novagen). The T-vector was digested with EcoRI and HindIII and subcloned into the multiple cloning sites of the promoterless Renilla luciferase reporter gene vector pRL-null (Promega). Basal expression of luciferase activity of the PAI-1 promoter vector was detected by the PAI Full (Ϫ747/15) luciferase vector. The 5Ј deletion mutants were generated by PCR with the 5Ј primers complementary to the PAI-1 gene sequence. Deletion mutants of PAI-1 promoter vectors were constructed as follows: PAI 1F (Ϫ553/15) luciferase, PAI 2F (Ϫ313/15) luciferase, PAI 3F (Ϫ260/15) luciferase, and PAI 4F (Ϫ205/15) luciferase. Point mutation of PAI-1 promoter vectors was also constructed. Basal expression of luciferase activity of PAI-1 promoter vector was detected by the PAI Full luciferase vector, which has a normal Ets-1-like site (5Ј-GGACATCCGGGAG-3Ј). The mutation vector has 2 point mutations in the Ets-1-like site as underlined (5Ј-GTTCATCCGGGAG-3Ј).
DNA Transfection and Luciferase Assay
ECV cells were cultured to Ϸ80% confluence. The cells were cotransfected with each PAI-1 promoter Renilla luciferase fusion DNA reporter construct (20 g of pRL vector) and a Firefly luciferase pGL vector to control for transfection efficiency (20 g) introduced by electroporation (240 V, 960 microfarad). These cells were cultured in DMEM supplemented with 10% calf serum for 20 hours, stimulated with bFGF (10 ng/mL) in DMEM containing 10% calf serum for 24 hours, and harvested. Cell lysate luciferase activity was measured with the use of a Dual-Luciferase Reporter Assay System (Promega) and luminometer (Turner Design). Normalized luciferase activity was calculated as the ratio of luciferase activity to control vector activity. Results for each reporter construct were expressed as percent induction compared with results in transfected unstimulated cells.
Electrophoretic Mobility Shift Assay
For electrophoretic mobility shift assay (EMSA), ECV cells were stimulated for 2 hours with bFGF before nuclear extracts were prepared. The oligonucleotide (ACGCTAGGACATCCGGGAG-CATG) spanning the Ets-1-like site (as underlined above) in the human PAI-1 promoter was end-labeled with [␣-32 P]dCTP by the Klenow fragment of DNA polymerase I and purified. Nuclear extracts (0.3 g) were incubated with the labeled oligonucleotide. DNA-protein complexes were separated from free probe by 5% nondenaturing polyacrylamide gel, and autoradiography was performed. Specificity was determined by the addition of an excess of unlabeled (cold) oligonucleotide to the nuclear extracts before formation of DNA-protein complexes.
Statistical Analysis
Data are meanϮSEM. Differences were assessed by ANOVA with the Bonferroni least significant post hoc tests for comparisons within multiple groups. Significance was defined as PϽ0.05.
Results
Effects of bFGF on PAI-1 Expression in ECs
A 2.1-fold increase in PAI-1 mRNA expression induced by bFGF was seen with HUVECs, as assessed by Northern blotting (see online Figure IA , which can be accessed at http://atvb.ahajournals.org). The baseline concentration of PAI-1 in the conditioned media of HUVECs was 181.7Ϯ32.7 ng/mL (nϭ4, ELISA). bFGF increased PAI-1 protein accumulation in the media in a concentration-dependent fashion (online Figure IB) . Peak effects were seen with 10 ng/mL (1.8Ϯ0.3-fold over control). Baseline activity of PAI-1 in the conditioned media was 12.0Ϯ0.6 arbitrary units per milliliter at 4 hour (nϭ4). bFGF increased PAI-1 activity at a concentration of 0.1 ng/mL (1.7Ϯ0.4-fold over control) and 1 ng/mL (2.3Ϯ1.1-fold over control). At 10 and 100 ng/mL, PAI-1 activity somewhat diminished (1.4Ϯ0.4-fold over control and 1.5Ϯ0.8-fold over control, respectively). The baseline concentration of tPA in the conditioned media of HUVECs was 22.1Ϯ2.2 ng/mL (nϭ4, ELISA). bFGF increased tPA protein accumulation in the media (24.9Ϯ2.7 at 1 ng/mL and 24.0Ϯ2.8 at 10 ng/mL, PϽ0.05).
An increase in PAI-1 mRNA expression was seen in ECV cells as assessed by Northern blotting (see online Figure IC ). The expression of PAI-1 mRNA by bFGF was increased in a concentration-dependent fashion, with a 1.4-fold increase over control at 10 ng/mL and a 2.0-fold increase at 100 ng/mL. The baseline concentration of PAI-1 in the conditioned media of ECV cells was 254Ϯ28 ng/mL (nϭ5, ELISA). bFGF increased PAI-1 protein accumulation in the media in a concentration-dependent fashion (see online Figure ID) . Peak effects were seen with 10 ng/mL bFGF (1.9Ϯ0.2-fold over control). The response was diminished somewhat with concentrations of 100 ng/mL (1.4Ϯ0.2-fold over control). The baseline concentration of tPA in the conditioned media of ECV cells was 0.71Ϯ0.05 ng/mL (nϭ4, ELISA). bFGF increased tPA protein accumulation in the media (0.88Ϯ0.05 at 1 ng/mL and 0.93Ϯ0.02 at 10 ng/mL, PϽ0.01). Total protein content in the conditioned media was not altered by bFGF in HUVECs and EVC cells (results not shown).
Effects of PD 98059 and Actinomycin D on PAI-1 mRNA
To investigate the intracellular mechanisms involved in the induction of PAI-1 mRNA, ECV cells were treated for 1 hour with each of the various inhibitors of intracellular signaling pathway before the addition of bFGF ( Figure 1A) . Inhibition of extracellular signal-regulated kinase (ERK) kinase with PD98059 blocked basal and bFGF-stimulated PAI-1 mRNA levels. In contrast, GF109203X, an inhibitor of the protein kinase C pathway, and genistein, an inhibitor of tyrosine kinase, had no significant effect. ␤-Actin mRNA levels did not change in any experimental conditions. To determine whether bFGF influences PAI-1 mRNA half-life, ECV cells were stimulated with bFGF for 2 hours, medium was changed, actinomycin D (5 g/mL) was added with or without bFGF, and cells were incubated for up to 6 hours ( Figure 1B) . The rate of PAI-1 mRNA decrease was not changed by bFGF, suggesting that the PAI-1 mRNA increase by bFGF was due to an increase of transcription from the PAI-1 promoter.
Determination of DNA Regions Critical for Basal and bFGF-Inducible PAI-1 Transcriptional Activity
To identify the 5Ј flanking region of the PAI-1 gene responsible for the effects of bFGF, transient transfections with several PAI-1 promoter-luciferase reporter constructs were performed in ECV cells (see online Figure IIA , which can be accessed at http://atvb.ahajournals.org). Higher basal promoter activity was observed in 1F and 2F, suggesting that the region between Ϫ747 and Ϫ553 bp may contain a repressor element (see online Figure IIB ). bFGF increased promoterdriven luciferase activity by 67Ϯ16% (see online Figure IIC , nϭ18). Relative to the largest promoter fragment tested, bFGF effect was reduced with deletion of the region at Ϫ747 to Ϫ553 bp and Ϫ553 to Ϫ313 bp. Deletion of the region at Ϫ313 to Ϫ260 bp completely abolished the bFGF effect. Deletion of the region at Ϫ260 to Ϫ205 bp resulted in no further reduction. These data indicate that the major sequence determinant of responsiveness resides between Ϫ313 and Ϫ260 bp. To determine whether a protein that can bind to the Ets-1-like site was responsible for the effect of bFGF, EMSA was performed by using oligonucleotides corresponding to the PAI-1 Ets-1-like site. The oligonucleotide bound, besides a constitutive protein complex, a bFGF-inducible nuclear protein complex, suggesting that bFGF induced nuclear translocation and DNA binding of the Ets-1-like transcription factor to the PAI-1 promoter (Figure 2A ). The addition of a 10-to 100-fold excess of cold probe inhibited DNA-protein complex formation in a dose-dependent manner. The addition of the Ets-1/Ets-2 antibody inhibited DNA-protein complex formation. To further characterize the responsible region, a mutant construct containing a 2-nucleotide substitution in the Ets-1-like site was generated. Compared with the bFGFinduced increased promoter activity in the wild-type, substitution in the Ets-1-like site reduced bFGF stimulation ( Figure   Figure 1 . Effects of PD98059 and actinomycin D (AD) on PAI-1 mRNA. A, Effects of PD98059 (30 mol/L), GF109203X (2 mol/ L), and genistein (100 mol/L) on PAI-1 mRNA levels. ECV cells were incubated with or without indicated inhibitors for 1 hour, and then bFGF was added. Cells were incubated for 4 hours. Total RNA was isolated and analyzed by Northern blot. PAI-1 mRNA levels were analyzed by densitometry and normalized to ␤-actin signals. At the top is an autoradiograph representative of 3 separate experiments. *PϽ0.05 and **PϽ0.01 compared with control. B, Effects of AD on PAI-1 mRNA levels. ECV cells were pretreated with bFGF (100 ng/mL) for 2 hours. Each medium was changed, and AD (5 g/mL) was added with or without bFGF. The incubation continued for up to 6 hours. Total RNA was isolated and analyzed by Northern blot. PAI-1 mRNA levels were analyzed by densitometry and normalized to ␤-actin signals. At the top is an autoradiograph representative of 3 separate experiments.
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2B). These results suggest that the Ets-1-like site is critical for the effect of bFGF.
Effects of Fenofibric Acid
Fenofibric acid diminished PAI-1 mRNA expression in ECV cells in a dose-dependent manner, as assessed by Northern blotting ( Figure 3A ). Fenofibric acid markedly diminished but did not totally abolish the accumulation of PAI-1 protein elaboration from ECV cells exposed to bFGF ( Figure 3B ). At a concentration of 100 mol/L, it suppressed baseline PAI-1 accumulation by 75Ϯ17% (nϭ3) and suppressed the increase induced by bFGF by 65Ϯ15% (nϭ3). When fenofibric acid was present in the media of ECV cells transfected with the PAI-1 promoter-luciferase reporter construct, basal PAI-1 promoter activity and bFGF-stimulated PAI-1 promoter activity were diminished (nϭ4, Figure 3C ). Thus, fenofibric acid inhibited PAI-1 expression at least partly at the level of transcription. Fenofibric acid did not inhibit bFGF-induced nuclear translocation or DNA binding of Ets-1-like transcription factor to the PAI-1 promoter (Figure 2A ). Fenofibric acid decreased the baseline concentration of tPA in the media by 84Ϯ08% and suppressed the increased induced by bFGF by 82Ϯ10% (nϭ3). Cell viability and total protein in the conditioned media were unaffected by fenofibric acid at the concentrations used (results not shown).
Discussion
In the present study, bFGF was shown to influence the production of PAI-1 in ECs. A paradoxical decrease of PAI-1 activity with high concentrations of bFGF in the media of HUVECs may reflect coinduction of plasminogen activators by bFGF. 7, 8 Increased PAI-1 protein correlated with increased mRNA and activity of the PAI-1 promoter. The induction of PAI-1 was inhibited by the ERK kinase inhibitor, suggesting that an ERK kinase-dependent pathway is involved in the regulation of endothelial PAI-1 gene expression by bFGF. The results in the present study extend our previous observation that the ERK kinase pathway plays a critical role in mediating the response of PAI-1 to angiotensin II in smooth muscle cells 18 ; furthermore, these results offer a novel insight into the mechanism of PAI-1 gene response in 2 distinct vascular cell components. The concentrations of the inhibitors used were relevant in ECV cells. 19 -21 Search for the putative regulatory sequence in the promoter revealed a sterol Confluent ECV cells were serum-starved for 24 hours and incubated with fresh serumfree media containing FA for 24 hours and exposed to bFGF for 4 hours. The magnitude of expression of PAI-1 mRNA and of ␤-actin were determined by Northern blot (nϭ3). PAI-1 mRNA levels were analyzed by densitometry and normalized to ␤-actin signals. A representative autoradiograph is shown at the top. B, Effects of FA on the concentration of PAI-1 in conditioned medium of ECV cells. Confluent cells were serum-starved for 24 hours, incubated with fresh serum-free media containing FA (0 and 100 mol/L) for 24 hours, and exposed to bFGF (0 and 100 ng/mL) for 24 hours. Conditioned media were harvested, and concentrations of PAI-1 were assayed by Western blot (nϭ6). Values are fold increase over control without bFGF. C, Effects of FA (100 mol/L) on basal and bFGF-inducible PAI-1 transcriptional activity (nϭ4). Promoter activity was determined as it was for online 4 fibrosis, 5 and atherosclerosis. 11 Control of proteolysis is important for angiogenesis. PAI-1 may diversely modulate angiogenesis. Low PAI-1 levels may result in excessive proteolysis, failure of cell adhesion, prevention of coordinated EC sprouting, 22, 23 and inhibition of angiogenesis. Tumor cells fail to invade in PAI-1 knockout mice because of a lack of vascularization. 24 PAI-1 promoted angiogenesis by the inhibition of proteolysis, 25 suggesting that an inhibition of excessive proteolysis by PAI-1 may contribute to neovascularization. Alternatively, inhibition of proteolysis can also inhibit angiogenesis because of the inhibition of fibrinolysis in the provisional matrix, 26 which might affect EC migration. Ets-1 modulates the angiogenic properties of ECs, 27 and growth factors that promote angiogenesis may also contribute to atherosclerotic plaque development. 28 Thus, proteolysis mediated by plasmin requires tight control during angiogenic processes, and induction of PAI-1 by bFGF as shown in the present study may contribute to this fine control of neovascularization.
Fenofibric acid diminished the increased accumulation of PAI-1 induced by the exposure of cells to bFGF. Because basal accumulation of PAI-1 was affected also by fenofibric acid, constitutive synthesis was modified as well. Fenofibric acid binds and activates PPAR␣, and activation of PPAR␣ negatively influences the AP-1-dependent pathway. 29 In the present study, deletion of the promoter region containing an AP-1-like site inhibited the effect of bFGF, and EMSA suggested that fenofibric acid did not inhibit nuclear translocation or DNA binding of the Ets-1-like transcription factor to the PAI-1 promoter. Thus, the inhibition of PAI-1 synthesis by fenofibric acid may involve the AP-1 activation pathway.
The potential consequences of fenofibric acid action are of particular clinical interest. Use of fibric acid derivatives decreases the incidence of cardiac events in patients with coronary artery disease and low LDL levels although only a modest increase in HDL is induced. 30 Although increased local fibrinolysis may induce degradation of the extracellular matrix and destabilization of advanced plaques, reduced PAI-1 expression by ECs may shift the local balance to increased fibrinolytic capacity in blood that could limit the extent of acute thrombosis after plaque rupture. A shift in the local fibrinolytic balance toward increased fibrinolysis may decrease thrombotic risk, thereby contributing to the clinical benefit seen with fibrates independent of their salutary effects on lipids. For determination of promoter activity raw data were tabulated as the ratio of firefly luciferase activity to that of Renilla luciferase activity (n=18), and values were reported as relative to the value for the control plasmid (assigned a value of 100). *p<0.05 and **p<0.01 compared to control. 
Online only supplement
